Aclaris Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $2,766 | $2,398 | $17,570 | $9,282 |
Gross Profit | 857 | 558 | 11,142 | 8,434 |
EBITDA | -12,354 | -13,388 | -43,161 | -31,577 |
EBIT | -12,554 | -13,631 | -43,389 | -31,796 |
Net Income | -10,986 | -16,941 | -1,491 | -29,261 |
Net Change In Cash | 2,766 | 2,398 | 17,570 | 9,282 |
Free Cash Flow | -12,308 | -20,950 | -7,202 | -24,641 |
Cash | 22,834 | 35,841 | 39,878 | 39,040 |
Basic Shares | 71,291 | 71,074 | 70,866 | 70,807 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $31,249 | $29,752 | $6,761 | $6,482 |
Gross Profit | 13,168 | 17,792 | 2,048 | 1,349 |
EBITDA | -134,408 | -79,657 | -41,045 | -49,588 |
EBIT | -135,271 | -80,454 | -41,968 | -50,912 |
Net Income | -88,481 | -88,662 | -114,281 | -51,154 |
Net Change In Cash | 31,249 | 29,752 | 6,761 | 6,482 |
Cost of Revenue | 17,928 | 5,286 | -13,874 | |
Free Cash Flow | -79,634 | -68,172 | -52,442 | -39,086 |
Cash | 39,878 | 45,277 | 27,349 | 54,131 |
Basic Shares | 69,808 | 65,213 | 56,730 | 42,539 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.15 |
2024-03-31 | -$0.24 |
2023-12-31 | -$0.02 |
2023-09-30 | -$0.41 |
